These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 23982145)
1. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release. Kola B; Wittman G; Bodnár I; Amin F; Lim CT; Oláh M; Christ-Crain M; Lolli F; van Thuijl H; Leontiou CA; Füzesi T; Dalino P; Isidori AM; Harvey-White J; Kunos G; Nagy GM; Grossman AB; Fekete C; Korbonits M FASEB J; 2013 Dec; 27(12):5112-21. PubMed ID: 23982145 [TBL] [Abstract][Full Text] [Related]
2. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. Kola B; Farkas I; Christ-Crain M; Wittmann G; Lolli F; Amin F; Harvey-White J; Liposits Z; Kunos G; Grossman AB; Fekete C; Korbonits M PLoS One; 2008 Mar; 3(3):e1797. PubMed ID: 18335063 [TBL] [Abstract][Full Text] [Related]
3. Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. Lim CT; Kola B; Feltrin D; Perez-Tilve D; Tschöp MH; Grossman AB; Korbonits M Mol Cell Endocrinol; 2013 Jan; 365(2):303-8. PubMed ID: 23178796 [TBL] [Abstract][Full Text] [Related]
4. CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus. Scerif M; Füzesi T; Thomas JD; Kola B; Grossman AB; Fekete C; Korbonits M J Endocrinol; 2013 Oct; 219(1):79-88. PubMed ID: 23884964 [TBL] [Abstract][Full Text] [Related]
6. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764 [TBL] [Abstract][Full Text] [Related]
7. The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake. Senin LL; Al-Massadi O; Folgueira C; Castelao C; Pardo M; Barja-Fernandez S; Roca-Rivada A; Amil M; Crujeiras AB; Garcia-Caballero T; Gabellieri E; Leis R; Dieguez C; Pagotto U; Casanueva FF; Seoane LM PLoS One; 2013; 8(11):e80339. PubMed ID: 24303008 [TBL] [Abstract][Full Text] [Related]
8. Bladder function in a cannabinoid receptor type 1 knockout mouse. Füllhase C; Campeau L; Sibaev A; Storr M; Hennenberg M; Gratzke C; Stief C; Hedlund P; Andersson KE BJU Int; 2014 Jan; 113(1):144-51. PubMed ID: 24053792 [TBL] [Abstract][Full Text] [Related]
9. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084 [TBL] [Abstract][Full Text] [Related]
10. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner. Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673 [TBL] [Abstract][Full Text] [Related]
11. Ghrelin-induced orexigenic effect in rats depends on the metabolic status and is counteracted by peripheral CB1 receptor antagonism. Alen F; Crespo I; Ramírez-López MT; Jagerovic N; Goya P; de Fonseca FR; de Heras RG; Orio L PLoS One; 2013; 8(4):e60918. PubMed ID: 23565287 [TBL] [Abstract][Full Text] [Related]
12. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003 [TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor 1 modulates the autophagic flux independent of mTOR- and BECLIN1-complex. Hiebel C; Kromm T; Stark M; Behl C J Neurochem; 2014 Nov; 131(4):484-97. PubMed ID: 25066892 [TBL] [Abstract][Full Text] [Related]
14. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice. Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481 [TBL] [Abstract][Full Text] [Related]
15. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Jourdan T; Djaouti L; Demizieux L; Gresti J; Vergès B; Degrace P Diabetes; 2010 Apr; 59(4):926-34. PubMed ID: 20110567 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Cannabinoid Receptor 1 Can Influence the Lipid Metabolism in Mice with Diet-Induced Obesity. Wei LW; Yuan ZQ; Zhao MD; Gu CW; Han JH; Fu L Biochemistry (Mosc); 2018 Oct; 83(10):1279-1287. PubMed ID: 30472964 [TBL] [Abstract][Full Text] [Related]
20. Rimonabant inhibits proliferation, collagen secretion and induces apoptosis in hepatic stellate cells. Dai E; Zhang J; Zhang D; Yang L; Wang Y; Jiang X; Ye L; Li X; Liu H; Ma J; Jiang H Hepatogastroenterology; 2014 Oct; 61(135):2052-61. PubMed ID: 25713910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]